Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludrocortisone and Stress in Borderline Personality Disorder
NCT05310253Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Feb 2022
- Primary completion
- Mar 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of fludrocortisone in borderline personality disorder (BPD) (8 arms), sponsored by Charité – Universitätsmedizin Berlin. Primary endpoint: Multifaceted Empathy Test. Started Feb 2022; status: completed.
02
Drugs
fludrocortisone
03
Conditions
borderline personality disorder (BPD)
Beyond the preview
Go deeper on NCT05310253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05310253.